Themes — melanoma patient and carer experience¶

Each theme below is supported by at least two independent sources. Single-source observations are held in sources.md and are not promoted here. No private individual is named or quoted. Ethics: README.md.

A mixed-methods systematic review of 14 studies (10 quantitative, 3 qualitative, 1 mixed-methods) searched 2000–November 2019 found informational care and unmet needs the most commonly reported, followed by psychological, then social, then physical; needs were present throughout the cancer journey and varied by stage (Fu 2020, PMID 32342223).
A qualitative systematic review with metasynthesis of 14 studies (16 papers), updating a 2010 review that had found only two eligible studies, identified 15 categories of need and experience across the skin cancer population (Bath-Hextall 2017, PMID 27775838).
A meta-narrative study of 214 patient-authored accounts from melanoma and cancer support websites in four countries organised supportive-care needs across three periods — lead-up to diagnosis; diagnosis, treatment and recovery; post-treatment and recurrence — with information needs recurring in all three (Lamprell 2018, PMID 29173015).

Why it matters. The clinical literature treats melanoma's problems as diagnostic and therapeutic. The patient literature consistently ranks not knowing above not being treated.

T2. Fear of recurrence is the defining burden of localised disease, and it is resistant to intervention¶

Among 51 survivors of localised cutaneous melanoma (mean age 49.5 years, 67% female) recruited from an academic dermatology practice, fear of recurrence was assessed with the Fear of Cancer Recurrence Inventory short form, on which a score of ≥13 of a possible 36 identifies clinically significant fear (Mahama 2024, PMID 38353983).
The MELACARE randomised controlled trial in 153 patients with surgically treated stage IA–IIA melanoma tested a nurse-led intervention combining skin-self-examination technique with metacognitive strategies against usual care. At 6 months fear of recurrence was lower in the intervention arm but not significantly so (−0.86, 95% CI −3.34 to 1.62), while health-related quality of life (18%, 3–32), patient activation (0.43, 0.15–0.71) and confidence in self-examination did improve significantly (Hansen 2025, PMID 40504479).
In uveal melanoma survivors, distress trajectories have been followed for seven years (Brown 2023, PMID 36848060) and 2–5-year fear of recurrence predicted from post-treatment symptoms and functional problems (Brown 2023, PMID 34850324).

Why it matters. More clinic visits are not the answer: MELFO's randomised comparison of reduced against conventional follow-up found no difference in any patient-reported outcome and >97% satisfaction in both arms (Moncrieff 2022, PMID 35866644). The one trial designed specifically to reduce fear of recurrence improved everything except fear of recurrence.

T3. Immunotherapy created a new problem: prognostic uncertainty as a source of harm¶

In a qualitative study of 42 patients and 10 caregivers (median age 67 years, 68% male, 62% with melanoma), four themes emerged: the oncology team shaped hopeful expectations of immunotherapy including as a potential cure among those with melanoma; distress from prognostic uncertainty particularly affected patients with toxicity or progressive disease; patients without long-term responses experienced overwhelming disappointment; and patients and caregivers held conflicting preferences for prognostic information (Boulanger 2025, PMID 39038253).
In-depth interviews with 20 bereaved carers across three Australian metropolitan melanoma centres found uncertainty dominating the experience — shock at diagnosis after sometimes innocuous vague symptoms, and an unclear prognosis arising from the interplay between an uncertain disease trajectory and ambiguous expectations of immune and targeted therapies (Fox 2019, PMID 30515757).
A companion study of the same carer population found them struggling to reconcile the positive discourse around long-term disease control with the underlying unpredictability of individual response; expectations that these therapies necessarily provide longer survival were evident, and difficulty in prognostication combined with a desire to maintain hope produced lack of preparedness for treatment failure and end of life (Fox 2020, PMID 32338133).

Why it matters. This is a harm generated by success. The same durable-response plateau that makes melanoma the reference case for immunotherapy (Wolchok 2025, PMID 39282897) makes individual prognosis less predictable than in the chemotherapy era, and three independent qualitative studies identify the resulting uncertainty as itself damaging.

T4. Carers carry a distinct and measurable burden¶

Bereaved carers of people with metastatic melanoma described uncertainty as the dominant quality of their experience and reported that it increased the complexity of care planning (Fox 2019, PMID 30515757), and separately that it left them unprepared for end of life (Fox 2020, PMID 32338133).
Caregivers participated alongside patients in the prognostic-uncertainty study and reported preferences for prognostic information that sometimes conflicted with the patient's (Boulanger 2025, PMID 39038253).
A scoping review of caregivers of melanoma and sarcoma patients screened 325 studies and included 16, cataloguing the assessment instruments used and identifying high stress, anxiety and caregiving burden with psychological, social and economic repercussions (Lleshi 2026, PMID 41827744).

Why it matters. Carer report and patient report are different data and are kept separate throughout this layer. Where they diverge — as they do on prognostic-information preferences — the divergence is the finding.

T5. Self-examination is both the main detection mechanism and a source of anxiety¶

In the MELFO randomised trial, self-examination was the method of recurrence detection for 75.8% of experimental-arm and 76.2% of control-arm patients (P = .41) across 388 sentinel-node-negative patients, with no evidence of diagnostic delay under reduced-frequency follow-up (Moncrieff 2022, PMID 35866644).
Structured skin-self-examination skills training improved early detection of new melanomas by patients and their partners in a randomised clinical trial (Robinson 2016, PMID 27367303), with digital, remote and internet-delivered variants subsequently randomised (Manne 2022, PMID 34637495; Robinson 2020, PMID 32761987; Robinson 2014, PMID 24418949).
Patients' own views about skin self-examination after treatment for localised melanoma have been studied directly (Dieng 2019, PMID 31090868), and the MELACARE intervention combined self-examination training with metacognitive strategies specifically because the two are entangled (Hansen 2025, PMID 40504479).
The USPSTF found evidence insufficient to assess the balance of benefits and harms of counselling adults about skin self-examination (Grossman 2018, PMID 29558558), and the supporting evidence review found that one trial of self-examination produced an increase in skin procedures without detecting additional atypical nevi or skin cancers (Henrikson 2018, PMID 29558557).

Why it matters. Patients detect three quarters of their own recurrences, and the same behaviour that achieves this is the behaviour that keeps the disease psychologically present. The intervention literature has not resolved that tension.

T6. Financial burden falls hardest on younger patients¶

In a cross-sectional survey of 106 advanced melanoma survivors treated with immunotherapy (39% response; median 36.4 months since starting immunotherapy, range 14.2–133.9), measured with the Comprehensive Score for Financial Toxicity alongside the EORTC QLQ-C30, patients under 65 reported significantly higher financial toxicity than older patients (P < .001), and financial toxicity correlated with quality of life (P < .001) after controlling for age (Thom 2021, PMID 33103948).
Melanoma's economic signature supports the mechanism: per-person healthcare expenditure is lower than for other non-skin cancers (adjusted marginal difference −$3,369, 95% CI −$5,934 to −$804) (Olateju 2024, PMID 39612258), while years of life lost per metastatic patient are 16–23 across twelve countries because the disease strikes younger than most solid tumours (Thiam 2016, PMID 26531249).
Costs of ipilimumab–nivolumab therapy and its adverse events have been modelled separately (Gautron Moura 2022, PMID 36612030).

Why it matters. Melanoma is not an expensive cancer per patient, but it takes more working years than most, and the financial harm concentrates in people of working age.

T7. Genomic risk information is generally well received, and its effects on behaviour are self-reported¶

Semistructured interviews with 30 participants (aged 24–69, 50% female; 12 low-risk, 8 average-risk, 10 high-risk) who had received personalised melanoma genomic risk information in a pilot trial found many reporting happiness, reassurance and new knowledge; some reported short-term negative emotional reactions that dissipated; most, particularly those with average or high-risk results, reported making positive behaviour changes (Fenton 2019, PMID 30580464).
In uveal melanoma, where prognostic genomic testing predicts metastatic risk without an intervention that modifies it, how clinicians communicate genomic results and their prognostic impact has been studied qualitatively (Müller 2026, PMID 41203514).

Why it matters. The reported behaviour change is self-reported and short-term. The wider evidence is that behavioural interventions reliably change sun-protection behaviour without reliably reducing sunburn (Henrikson 2018, PMID 29558557) — so a reported behaviour change should not be read as a reduced risk.

T8. The lived experience of acral, mucosal and skin-of-colour melanoma is almost entirely absent from this literature¶

The principal qualitative syntheses draw on studies from Australia, the UK, the US and Northern Europe (Bath-Hextall 2017, PMID 27775838; Fu 2020, PMID 32342223), and the largest patient-authored corpus covered four countries (Lamprell 2018, PMID 29173015).
These are precisely the populations in which melanoma is most often cutaneous and light-skinned. People with skin of colour are diagnosed at more advanced stages with worse survival and a different subtype mix (Brunsgaard 2023, PMID 35533771), and acral melanoma survival disparities persist after adjustment for socioeconomic status and stage (Yan 2022, PMID 34363907).
The clinical literature has quantified these disparities repeatedly; the experience literature has not reached the populations they describe.

Why it matters. This is recorded as a theme because the absence is systematic and its direction is known: the groups with the worst melanoma outcomes are the groups whose experience is least documented.